Methylene blue in the critical care setting (2025)

Peer-Reviewed Study · Emati PR, Nagaradona T, Raghove V, Jagirdhar GSK, Surani S · September 9, 2025

Emati PR et al., 2025-09-09: Critical-care review of methylene blue describing its mechanism as guanylate cyclase inhibition with vasoconstriction, which is the pharmacological basis for its interaction with nitric-oxide-mediated vasodilatation and with vasopressor requirements.

It has a role in vasoconstriction, methemoglobin reduction, inhibition of guanylate cyclase, and anti-inflammatory effects.

Emati PR et al., 2025-09-09: Critical-care review of methylene blue describing its mechanism as guanylate cyclase inhibition with vasoconstriction, which is the pharmacological basis for its interaction with nitric-oxide-mediated vasodilatation and with vasopressor requirements. C6 mechanism (nitric oxide / guanylate cyclase axis, vasopressor sparing). Funder/conflicts not stated in abstract. The quoted line states the mechanism but not a specific drug-drug interaction, so confidence MEDIUM: it explains why methylene blue antagonises NO-mediated vasodilatation rather than reporting a measured interaction with a named nitrate or vasopressor. Study type: review.